Best Practice & Research Clinical Gastroenterology最新文献

New weapons for the management of perianal Crohn's disease 治疗肛周克罗恩病的新武器

IF 4 3区医学

Best Practice & Research Clinical Gastroenterology Pub Date : 2025-08-01 DOI: 10.1016/j.bpg.2025.102030

Clelia Cicerone , Paulo Gustavo Kotze

引用次数: 0

Reaching the therapeutic ceiling in IBD: Can Advanced Combination Treatment (ACT) offer a solution? 达到IBD治疗上限：高级联合治疗（ACT）能否提供解决方案？

IF 4 3区医学

Best Practice & Research Clinical Gastroenterology Pub Date : 2025-08-01 DOI: 10.1016/j.bpg.2025.101981

Virginia Solitano , Jurij Hanžel , Maria Manuela Estevinho , Rocio Sedano , Luca Massimino , Federica Ungaro , Vipul Jairath

{"title":"Reaching the therapeutic ceiling in IBD: Can Advanced Combination Treatment (ACT) offer a solution?","authors":"Virginia Solitano , Jurij Hanžel , Maria Manuela Estevinho , Rocio Sedano , Luca Massimino , Federica Ungaro , Vipul Jairath","doi":"10.1016/j.bpg.2025.101981","DOIUrl":"10.1016/j.bpg.2025.101981","url":null,"abstract":"<div><div>The term Advanced Combination Treatment (ACT) involves the combination of at least two biologics or the use of a biologic with a small molecule drug, each with different mechanisms of action. This narrative review evaluates the current evidence supporting ACT in inflammatory bowel disease (IBD), focusing on preclinical studies, real-world evidence, and randomized controlled trials. A systematic review of randomized controlled trials has concluded that ACT significantly improves clinical outcomes, without significant safety concerns in patient with IBD. However, variability in trial designs and the lack of standardized outcome measures have led to initiatives aimed at mitigating these issues through a clear expert consensus. While the evidence for ACT in IBD is compelling, substantial challenges remain in standardizing treatment protocols and ensuring long-term safety. In the meantime, the use of ACT in clinical practice remains off-label and requires careful consideration of patient-specific factors. Future clinical trials should consider robust biomarkers for patient selection and leverage mechanistic insights to select combination components.</div></div>","PeriodicalId":56031,"journal":{"name":"Best Practice & Research Clinical Gastroenterology","volume":"77 ","pages":"Article 101981"},"PeriodicalIF":4.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144766470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Copyright Information 版权信息

IF 4 3区医学

Best Practice & Research Clinical Gastroenterology Pub Date : 2025-08-01 DOI: 10.1016/S1521-6918(25)00065-4

引用次数: 0

Treatment targets in IBD: is it time for new strategies? IBD的治疗目标：是时候采取新策略了吗？

IF 4 3区医学

Best Practice & Research Clinical Gastroenterology Pub Date : 2025-08-01 DOI: 10.1016/j.bpg.2025.101990

Fabrizio Fanizzi , Ferdinando D'Amico , Laurent Peyrin-Biroulet , Silvio Danese , Axel Dignass

{"title":"Treatment targets in IBD: is it time for new strategies?","authors":"Fabrizio Fanizzi , Ferdinando D'Amico , Laurent Peyrin-Biroulet , Silvio Danese , Axel Dignass","doi":"10.1016/j.bpg.2025.101990","DOIUrl":"10.1016/j.bpg.2025.101990","url":null,"abstract":"<div><div>Inflammatory bowel diseases’ traditional management focused primarily on symptom control, often failing to prevent long-term complications such as disease progression, disabilities, hospitalizations and surgeries. The introduction of biologics and small molecules has revolutionized IBD management, enhancing inflammation control. A pivotal advance in this field is represented by the Treat-to-Target approach, which prioritizes the achievement of specific goals like endoscopic remission and biomarker normalization, thus moving beyond symptomatic relief. The STRIDE recommendations have been pivotal in shaping treatment goals, with STRIDE-II advancing this approach by adding timelines to established targets and suggesting histologic remission for UC and transmural healing for CD as supplementary objectives. Future strategies are expected to incorporate these outcomes, aiming for more comprehensive disease control. This review evaluates whether new therapeutic targets are required to address the unmet needs in IBD management and to further improve longterm patient outcomes.</div></div>","PeriodicalId":56031,"journal":{"name":"Best Practice & Research Clinical Gastroenterology","volume":"77 ","pages":"Article 101990"},"PeriodicalIF":4.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144766464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pregnancy and IBD: A practical guide for physicians 妊娠和IBD：给医生的实用指南

IF 4 3区医学

Best Practice & Research Clinical Gastroenterology Pub Date : 2025-08-01 DOI: 10.1016/j.bpg.2025.101996

Natália Sousa Freitas Queiroz , Federica Furfaro

引用次数: 0

The role of diet in inflammatory bowel disease: A comprehensive review of the literature 饮食在炎症性肠病中的作用：文献综述

IF 4 3区医学

Best Practice & Research Clinical Gastroenterology Pub Date : 2025-08-01 DOI: 10.1016/j.bpg.2025.101995

Ilaria Faggiani , Jacopo Fanizza , Sara Massironi , Ferdinando D'Amico , Mariangela Allocca , Federica Furfaro , Tommaso Lorenzo Parigi , Gionata Fiorino , Silvio Danese , Alessandra Zilli

{"title":"The role of diet in inflammatory bowel disease: A comprehensive review of the literature","authors":"Ilaria Faggiani , Jacopo Fanizza , Sara Massironi , Ferdinando D'Amico , Mariangela Allocca , Federica Furfaro , Tommaso Lorenzo Parigi , Gionata Fiorino , Silvio Danese , Alessandra Zilli","doi":"10.1016/j.bpg.2025.101995","DOIUrl":"10.1016/j.bpg.2025.101995","url":null,"abstract":"<div><div>Diet is increasingly recognized as a modifiable factor in the pathogenesis and management of inflammatory bowel disease (IBD), particularly in mild to moderate cases. While most evidence comes from pediatric studies, adult data, especially randomized controlled trials (RCTs), remain limited. Current guidelines recommend a Mediterranean diet for patients with IBD, avoiding fruits and vegetables during disease flares. Exclusive enteral nutrition (EEN) has demonstrated therapeutic potential in pediatric Crohn's disease (CD), but data in adults are less conclusive, partly due to issues with adherence. Clinicians must routinely monitor nutritional markers such as hemoglobin, iron status, vitamins, and albumin every 6–12 months, and supplement deficiencies as required. The presence of a dedicated nutrition specialist within IBD units could improve care, as nutrition also impacts psychological well-being. In addition, the role of the microbiome and how dietary interventions can modulate it to alleviate both inflammatory and functional symptoms warrant further exploration.</div></div>","PeriodicalId":56031,"journal":{"name":"Best Practice & Research Clinical Gastroenterology","volume":"77 ","pages":"Article 101995"},"PeriodicalIF":4.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144766466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

“Unraveling the mysteries of IBD: Innovations and insights into the management of Crohn's disease and ulcerative colitis” “揭开IBD的奥秘：克罗恩病和溃疡性结肠炎管理的创新和见解”

IF 4 3区医学

Best Practice & Research Clinical Gastroenterology Pub Date : 2025-08-01 DOI: 10.1016/j.bpg.2025.102035

Ferdinando D'Amico (Guest Editors), Sarah Bencardino (Guest Editors), Silvio Danese (Guest Editors)

引用次数: 0

Preface to special edition: Microbiome, inflammation and cancer 特别版前言：微生物组，炎症和癌症

IF 4 3区医学

Best Practice & Research Clinical Gastroenterology Pub Date : 2025-08-01 DOI: 10.1016/j.bpg.2024.101952

Benjamin H. Mullish, Gianluca Ianiro

引用次数: 0

Biobetters and biosimilars in inflammatory bowel disease 炎症性肠病的生物改良药和生物类似药

IF 4 3区医学

Best Practice & Research Clinical Gastroenterology Pub Date : 2025-08-01 DOI: 10.1016/j.bpg.2025.101992

Jacopo Fanizza , Ilaria Faggiani , Mariangela Allocca , Federica Furfaro , Alessandra Zilli , Tommaso Lorenzo Parigi , Clelia Cicerone , Gionata Fiorino , Laurent Peyrin-Biroulet , Silvio Danese , Pablo Andres Olivera , Ferdinando D'Amico

{"title":"Biobetters and biosimilars in inflammatory bowel disease","authors":"Jacopo Fanizza , Ilaria Faggiani , Mariangela Allocca , Federica Furfaro , Alessandra Zilli , Tommaso Lorenzo Parigi , Clelia Cicerone , Gionata Fiorino , Laurent Peyrin-Biroulet , Silvio Danese , Pablo Andres Olivera , Ferdinando D'Amico","doi":"10.1016/j.bpg.2025.101992","DOIUrl":"10.1016/j.bpg.2025.101992","url":null,"abstract":"<div><div>Biological therapies have revolutionized the management of inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC). Among these, biosimilars and biobetters represent a growing area of therapeutic development. Biosimilars are nearly identical copies of original biologic drugs (reference products) with comparable safety, efficacy, and quality, but they offer the advantage of reduced costs and broader access. In contrast, biobetters, while based on existing biologics, are engineered to enhance certain properties such as efficacy, safety, or dosing convenience. Both biosimilars and biobetters play an increasingly important role in IBD treatment, expanding options for patients and helping to address economic challenges in healthcare systems. This review explores the clinical application, benefits, and challenges associated with biosimilars and biobetters in IBD, focusing on their role in achieving therapeutic goals while optimizing patient access and cost-effectiveness.</div></div>","PeriodicalId":56031,"journal":{"name":"Best Practice & Research Clinical Gastroenterology","volume":"77 ","pages":"Article 101992"},"PeriodicalIF":4.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144766468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment sequencing in inflammatory bowel disease: Towards clinical precision medicine 炎症性肠病的治疗顺序：迈向临床精准医学

IF 4 3区医学

Best Practice & Research Clinical Gastroenterology Pub Date : 2025-08-01 DOI: 10.1016/j.bpg.2025.101994

Léa Sequier , Bénédicte Caron , Sailish Honap , Ludovic Caillo , Romain Altwegg , Patrick Netter , Mathurin Fumery , Anthony Buisson , Laurent Peyrin-Biroulet

{"title":"Treatment sequencing in inflammatory bowel disease: Towards clinical precision medicine","authors":"Léa Sequier , Bénédicte Caron , Sailish Honap , Ludovic Caillo , Romain Altwegg , Patrick Netter , Mathurin Fumery , Anthony Buisson , Laurent Peyrin-Biroulet","doi":"10.1016/j.bpg.2025.101994","DOIUrl":"10.1016/j.bpg.2025.101994","url":null,"abstract":"<div><div>Inflammatory bowel diseases, including Crohn's disease and ulcerative colitis, raise ongoing challenges in clinical management due to their variable courses and impact on patient quality of life. The emergence of advanced therapies, from biologics to small molecules, has prompted the need for effective sequencing strategies to optimize patient outcomes. To this date, there is no algorithm for treatment sequencing and physicians must select the safest and most effective treatment according to each individual patient. This review aims to explore the latest insights in treatment sequencing according to multiple criteria, such as prior use of anti-TNF alpha agents, prior surgery, disease phenotype and location, but also patient characteristics, such as age or history of malignancy. Treatment sequencing in IBD should be part of a clinical medicine approach and be tailored to individual patient characteristics, disease severity, and therapeutic response history. Indeed, a personalized approach of therapeutic management in inflammatory bowel diseases can improve long-term outcomes and quality of life. Ongoing research is essential to refine sequencing strategies, and better incorporate these advances into clinical practice.</div></div>","PeriodicalId":56031,"journal":{"name":"Best Practice & Research Clinical Gastroenterology","volume":"77 ","pages":"Article 101994"},"PeriodicalIF":4.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144766469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0